TY - JOUR T1 - Bone Metastasis in Primary Endometrial Carcinoma: Features, Outcomes, and Predictors JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 107 LP - 112 DO - 10.1097/IGC.0000000000000015 VL - 24 IS - 1 AU - Aera Yoon AU - Chel Hun Choi AU - Tae-Hyun Kim AU - June-Kuk Choi AU - Jin-Young Park AU - Yoo-Young Lee AU - Tae-Joong Kim AU - Jeong-Won Lee AU - Duk-Soo Bae AU - Byoung-Gie Kim Y1 - 2014/01/01 UR - http://ijgc.bmj.com/content/24/1/107.abstract N2 - Objectives This study aimed to describe the clinicopathologic characteristics and outcomes and to assess the predictors associated with prognosis in endometrial carcinoma that developed bone metastasis.Methods A retrospective review of medical records was performed to identify the patients with endometrial carcinoma who developed bone metastasis between October 1994 and May 2012.Results Of the 1185 patients with endometrial carcinoma, 22 (1.8%) were identified with bone metastasis, and 21 patients were analyzed in the study. Seventeen (80.9%) patients had advanced-stage disease (2009 International Federation of Gynecologists and Obstetricians stages III-IV). Four (19.0%) patients had a bone lesion at the diagnosis of endometrial cancer. The median time of recurrence to the bone in 17 patients was 9 months (range, 2–43 months). The median overall survival (OS) and survival after bone metastasis of the entire cohort were 33 months (range, 9–57 months) and 15 months (range, 12–17 months), respectively. The patients with bone metastasis at recurrence had significantly longer OS than those patients with bone metastasis at diagnosis of endometrial cancer (36 vs 13 months; P = 0.042). Metastasis to extrapelvic bone was significantly associated with longer OS (46 vs 19 months; P = 0.001) and longer survival after bone metastasis (25 vs 12 months; P = 0.002). Isolated bone recurrence without extraosseous metastases and extrapelvic bone metastasis revealed independent predictors for survival after bone metastasis (hazard ratio, 0.09; 95% confidence interval, 0.01–0.67; P = 0.019 and hazard ratio, 0.07; 95% confidence interval, 0.01–0.53; P = 0.01).Conclusions In endometrial carcinoma that develops bone metastasis, isolated bone recurrence and extrapelvic bone metastasis are significant predictors of prolonged survival after the diagnosis of bone metastasis. Further researches on the optimal treatment modality and factors that have the clinical implications are warranted. ER -